What happened with ALLO today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Allogene Therapeutics engineers healthy donors’ T cells to kill cancer cells or eliminate immune cells that drive autoimmune diseases. It is developing these CAR T-cell therapies as ready-made treatments. Its cema-cel program targets large B-cell lymphoma patients whose initial treatment has worked but who still have detectable traces of disease, aiming to treat them before relapse rather than simply monitor them.
The company remains in clinical development, with no approved products or product-sales revenue. Its revenue to date has come exclusively from its license agreement with Overland Therapeutics, rather than payments for treating patients. It has financed operations mainly through capital raising and needs additional funding to continue development and prepare for potential commercialization.
Reaching product sales depends on clinical evidence, regulatory approval and reliable manufacturing at commercial scale. Allogene also relies on licensed gene-editing technology from Cellectis for its cancer programs and Arbor for its autoimmune program. The cema-cel trial uses Foresight Diagnostics’ CLARITY test to select patients; Allogene expects an approved test will also be needed to identify eligible patients if cema-cel reaches the market.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Allogene hinges on clinical success and how long its cash lasts, but also depends on Servier for cema-cel rights and Arbor for autoimmune-program gene-editing technology.
Caribou Biosciences offers a comparison for Allogene's donor-derived CAR T approach to B-cell lymphoma, but the patients differ: Caribou's vispa-cel targets relapsed or refractory disease, while Allogene's cema-cel is being tested after successful initial treatment in newly diagnosed patients at high risk of relapse.
Allogene depends on Cellectis for the tools that edit its cancer-treatment cells—the TALEN technology—even as Cellectis develops competing donor-derived CAR T therapies and licenses technology to partners. Watch its ability and willingness to supply those tools: disruption could delay Allogene's oncology development or prevent commercialization.
CRISPR Therapeutics competes with Allogene across both cancer and autoimmune disease by developing gene-edited, donor-derived CAR T treatments. Its CAR T programs, rather than its approved blood-disorder treatment, are the relevant comparison for Allogene's pipeline.
Nkarta offers an alternative to Allogene's ALLO-329 for autoimmune disease: both use donor-derived cells prepared in advance, but Nkarta's NKX019 uses natural killer cells targeting CD19, while ALLO-329 uses T cells targeting CD19 and CD70. NKX019's autoimmune-disease studies are the comparison to watch.
Century Therapeutics competes with Allogene to treat B-cell-mediated autoimmune diseases with engineered immune cells prepared for off-the-shelf use. Watch CNTY-101 in the CARAMEL trial as a comparison for Allogene's ALLO-329; Century makes its cells from stem cells that can be expanded and turned into immune cells.
Fate Therapeutics tests a different production route for Allogene's off-the-shelf cancer-treatment approach: Fate turns engineered stem-cell lines into T cells, while Allogene starts with donor T cells. Ono funds Fate's solid-tumor development, including FT825 / ONO-8250 for HER2-expressing tumors, a different target from Allogene's ALLO-316 kidney-cancer program.
Artiva Biotherapeutics' AlloNK is another off-the-shelf immune-cell approach to the autoimmune diseases Allogene seeks to treat with ALLO-329, using natural killer cells rather than T cells. AlloNK's clinical progress and consistency of manufactured batches are worth watching alongside Allogene's development.
Sana Biotechnology and Allogene pursue engineered, off-the-shelf T-cell treatments for B-cell diseases; preventing immune rejection and keeping the treatment cells alive are central challenges for both.
Gilead Sciences' Kite already markets CAR T treatments for large B-cell lymphoma, setting an established treatment benchmark for Allogene's off-the-shelf cema-cel. Allogene is testing cema-cel after successful initial treatment in newly diagnosed patients at high risk of relapse, so the treatment setting matters when comparing results.
Bristol Myers Squibb's Breyanzi provides a commercial and clinical benchmark for Allogene's cema-cel in B-cell lymphoma CAR T treatment. Breyanzi's commercial performance and clinical results are the relevant comparison, while cema-cel is being tested as consolidation after successful initial treatment.
Allogene depends on diagnostic-test seller Natera's Foresight subsidiary to identify eligible ALPHA3 lymphoma patients using its CLARITY test for traces of remaining disease, known as MRD. Watch testing capacity and regulatory approvals: disruptions could slow enrollment and cema-cel development, and Allogene does not control the assay's approval process.
Autolus Therapeutics offers a commercial reference for Allogene's CAR T ambitions, but treats a different disease: its AUCATZYL uses patients' own cells for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, while Allogene develops donor-derived cema-cel for B-cell lymphoma. Watch AUCATZYL's uptake in the United States and United Kingdom; its EU launch remains on hold while Autolus assesses pricing and market-entry feasibility.
Fed Interest Rate Decision
For Allogene, the Fed’s decision on short-term interest rates matters because higher rates can increase interest earned on its cash, cash equivalents and investments, while lower rates can reduce that income.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates could raise the interest Allogene earns on its cash, cash equivalents and investments, partly offsetting the cost of funding its research and development.
If it comes in below expectations
Lower rates could reduce the interest Allogene earns on its cash, cash equivalents and investments, leaving less interest income to offset its research and development funding needs.
Bristol-Myers Squibb Co. earningsBMY
Bristol Myers Squibb’s report will show how Breyanzi is doing in B-cell lymphoma, giving Allogene a commercial benchmark for its investigational CAR T therapy cema-cel.
Look at Breyanzi’s commercial performance alongside relevant clinical progress. Strong results would show an established CAR T treatment holding a place in B-cell lymphoma care, while Allogene would still need to prove cema-cel’s value as consolidation after initial treatment for patients with detectable residual disease. Weak results would offer less support from this benchmark; Breyanzi’s treatment setting is different, so the two are not direct substitutes.
Allogene Therapeutics, Inc. earningsThis company
Allogene is using cash to advance clinical programs, and its report will show how research spending and cash use are moving together.
Read operating cash used alongside research and development spending, then check how cash, cash equivalents and investments changed. Slower cash use while research spending continues would suggest more time to advance programs; faster cash use without a corresponding rise in research spending would shorten the funding runway and increase pressure to raise money or change programs.
Natera, Inc. earningsNTRA
Natera’s report may show whether its Foresight business can keep CLARITY testing available, a service Allogene’s ALPHA3 trial relies on to identify eligible patients.
Watch what Natera says about Foresight’s testing capacity and relevant regulatory progress. Continued service and progress would reduce the risk that testing slows ALPHA3 screening and enrollment; disruption or regulatory delay could slow patient identification and cema-cel development, which Allogene does not control. Natera’s overall results cannot establish CLARITY’s accuracy or enrollment performance in ALPHA3.
Nkarta, Inc. earningsNKTX
Nkarta’s report may show progress in NKX019 autoimmune-disease studies, an off-the-shelf cell-treatment comparison for Allogene’s donor-derived T-cell candidate ALLO-329.
Look for whether NKX019’s autoimmune-disease studies advance and what Nkarta says about their clinical progress. Progress would add evidence that ready-made donor-derived cell treatments are moving through clinical testing, offering a comparison for ALLO-329; setbacks would weaken that broader support, but NKX019 uses natural killer cells, so its outcome cannot establish whether ALLO-329 works.
Cellectis S.A. earningsCLLS
Cellectis’s report may shed light on TALEN technology supply and support, which Allogene relies on to engineer its cancer-treatment cells.
Watch what Cellectis says about TALEN-related arrangements, supply capacity and support. Stable access would reduce the risk of disruption to Allogene’s engineered-cell development; limits on supply or cooperation could delay or impede its candidates and eventual commercialization. Progress in Cellectis’s own therapies would not substitute for results from Allogene’s trials.
